| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
29,260,000 |
| Market
Cap: |
230.28(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.27 - $9.89 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XBiotech is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies for treating a variety of diseases. Co. has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. An area of medical focus for Co. are therapies that block a substance naturally produced by body, known as interleukin-1 alpha, that mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting and inflammation. Co.'s product development includes: Natrunix program, which is for the indication of pancreatic cancer and rheumatoid arthritis, and Hutrukin program, which is for the indication of stroke.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simard John |
Chief Executive Officer |
• • • |
2017-05-24 |
4 |
D |
$8.17 |
$949,411 |
D/D |
(116,207) |
6,277,060 |
|
- |
|
| Simard John |
Chief Executive Officer |
• • • |
2017-05-24 |
4 |
OE |
$0.93 |
$223,608 |
D/D |
240,000 |
6,393,267 |
|
- |
|
| Han Queena |
VP Finance & HR |
• – – |
2016-11-15 |
4 |
S |
$15.00 |
$293,595 |
D/D |
(19,573) |
0 |
|
- |
|
| Han Queena |
VP Finance & HR |
• – – |
2016-11-15 |
4 |
OE |
$0.74 |
$14,484 |
D/D |
19,573 |
19,573 |
|
- |
|
| Han Queena |
VP Finance & HR |
• – – |
2016-09-08 |
4 |
S |
$15.00 |
$6,405 |
D/D |
(427) |
0 |
|
- |
|
| Han Queena |
VP Finance & HR |
• – – |
2016-09-08 |
4 |
OE |
$0.77 |
$329 |
D/D |
427 |
427 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2016-05-26 |
4 |
B |
$13.76 |
$279,115 |
I/I |
20,000 |
5,000 |
2.25 |
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2016-05-20 |
4 |
B |
$13.72 |
$20,618 |
I/I |
1,500 |
5,750 |
2.17 |
- |
|
| Simard John |
Director |
– • • |
2016-03-17 |
4 |
D |
$10.00 |
$5,000,000 |
D/D |
(500,000) |
6,153,267 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2016-03-17 |
4 |
A |
$10.00 |
$5,000,000 |
D/D |
500,000 |
3,898,600 |
|
- |
|
| Han Queena |
VP Finance / HR |
• – – |
2015-12-22 |
4 |
S |
$10.27 |
$102,743 |
D/D |
(10,000) |
0 |
|
- |
|
| Han Queena |
VP Finance / HR |
• – – |
2015-12-22 |
4 |
OE |
$0.72 |
$7,200 |
D/D |
10,000 |
10,000 |
|
- |
|
| Han Queena |
VP Finance / HR |
• – – |
2015-12-21 |
4 |
S |
$10.11 |
$102,616 |
D/D |
(10,000) |
0 |
|
- |
|
| Han Queena |
VP Finance / HR |
• – – |
2015-12-21 |
4 |
OE |
$0.72 |
$7,200 |
D/D |
10,000 |
10,000 |
|
- |
|
| Han Queena |
VP Finance / HR |
• – – |
2015-12-18 |
4 |
S |
$10.51 |
$106,354 |
D/D |
(10,000) |
0 |
|
- |
|
| Han Queena |
VP Finance / HR |
• – – |
2015-12-18 |
4 |
OE |
$0.72 |
$7,200 |
D/D |
10,000 |
10,000 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2015-11-25 |
4 |
GA |
$0.00 |
$0 |
I/I |
10,000 |
5,000 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2015-11-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
18,400 |
3,398,600 |
|
- |
|
| Stecher Michael |
Medical Director |
• – – |
2015-11-16 |
4 |
S |
$14.00 |
$25,200 |
D/D |
(1,800) |
0 |
|
- |
|
| Stecher Michael |
Medical Director |
• – – |
2015-11-16 |
4 |
OE |
$5.00 |
$9,000 |
D/D |
1,800 |
1,800 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2015-04-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
810,996 |
|
- |
|
| Mckenzie W Thorpe |
Director |
– • • |
2015-04-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,375,000 |
|
- |
|
| Simard John |
President, CEO & ChairmanOffic |
• • • |
2015-04-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,653,267 |
|
- |
|
| Vasella Daniel |
Director |
– • – |
2015-04-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
30,000 |
|
- |
|
124 Records found
|
|
Page 5 of 5 |
|
|
0.34 (4.14%) 
